{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:45:01Z","timestamp":1787874301572,"version":"build-2784847793"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270940"],"award-info":[{"award-number":["82270940"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10495-026-02258-6","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T12:37:49Z","timestamp":1768826269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ferroptosis and its role in immune modulation in breast cancer"],"prefix":"10.1007","volume":"31","author":[{"given":"Fen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahai H.","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujuan J.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9489-0627","authenticated-orcid":false,"given":"Changchun C.","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"2258_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"2258_CR2","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","volume":"186","author":"E Nolan","year":"2023","unstructured":"Nolan E, Lindeman GJ, Visvader JE (2023) Deciphering breast cancer: from biology to the clinic. Cell 186:1708\u20131728","journal-title":"Cell"},{"key":"2258_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","volume":"22","author":"F Ye","year":"2023","unstructured":"Ye F, Dewanjee S, Li Y et al (2023) Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer 22:105","journal-title":"Mol Cancer"},{"key":"2258_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","volume":"22","author":"Y Liu","year":"2023","unstructured":"Liu Y, Hu Y, Xue J et al (2023) Advances in immunotherapy for triple-negative breast cancer. Mol Cancer 22:145","journal-title":"Mol Cancer"},{"key":"2258_CR5","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1078-0432.CCR-16-3001","volume":"24","author":"LA Emens","year":"2018","unstructured":"Emens LA (2018) Breast cancer immunotherapy: facts and hopes. Clin Cancer Res 24:511\u2013520","journal-title":"Clin Cancer Res"},{"key":"2258_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","volume":"42","author":"G Lei","year":"2024","unstructured":"Lei G, Zhuang L, Gan B (2024) The roles of ferroptosis in cancer: tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell 42:513\u2013534","journal-title":"Cancer Cell"},{"key":"2258_CR7","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.ymthe.2021.03.022","volume":"29","author":"H Wang","year":"2021","unstructured":"Wang H, Cheng Y, Mao C et al (2021) Emerging mechanisms and targeted therapy of ferroptosis in cancer. Mol Ther 29:2185\u20132208","journal-title":"Mol Ther"},{"key":"2258_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cac2.12250","volume":"42","author":"L Zhao","year":"2022","unstructured":"Zhao L, Zhou X, Xie F et al (2022) Ferroptosis in cancer and cancer immunotherapy. Cancer Commun (Lond) 42:88\u2013116","journal-title":"Cancer Commun (Lond)"},{"key":"2258_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D et al (2024) Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther 9:55","journal-title":"Signal Transduct Target Ther"},{"key":"2258_CR10","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1080\/15548627.2023.2218764","volume":"19","author":"Y Xie","year":"2023","unstructured":"Xie Y, Kang R, Klionsky DJ, Tang D (2023) GPX4 in cell death, autophagy, and disease. Autophagy 19:2621\u20132638","journal-title":"Autophagy"},{"key":"2258_CR11","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/cac2.12487","volume":"43","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Sun L, Guo J, Ma J (2023) The crosstalk between ferroptosis and anti-tumor immunity in the tumor microenvironment: molecular mechanisms and therapeutic controversy. Cancer Commun (Lond) 43:1071\u20131096","journal-title":"Cancer Commun (Lond)"},{"key":"2258_CR12","doi-asserted-by":"crossref","unstructured":"Sanhueza S, Simon L, Cifuentes M, Quest AFG (2023) The adipocyte-macrophage relationship in cancer: a potential target for antioxidant therapy. Antioxidants (Basel) 12:126","DOI":"10.3390\/antiox12010126"},{"key":"2258_CR13","doi-asserted-by":"publisher","first-page":"e18044","DOI":"10.1111\/jcmm.18044","volume":"28","author":"A Ge","year":"2024","unstructured":"Ge A, He Q, Zhao D et al (2024) Mechanism of ferroptosis in breast cancer and research progress of natural compounds regulating ferroptosis. J Cell Mol Med 28:e18044","journal-title":"J Cell Mol Med"},{"key":"2258_CR14","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41392-022-01046-3","volume":"7","author":"W Gao","year":"2022","unstructured":"Gao W, Wang X, Zhou Y, Wang X, Yu Y (2022) Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Signal Transduct Target Ther 7:196","journal-title":"Signal Transduct Target Ther"},{"key":"2258_CR15","doi-asserted-by":"crossref","unstructured":"Demuynck R, Efimova I, Naessens F, Krysko DV (2021) Immunogenic ferroptosis and where to find it? J Immunother Cancer 9:e003430","DOI":"10.1136\/jitc-2021-003430"},{"key":"2258_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B (2022) Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer 22:381\u2013396","journal-title":"Nat Rev Cancer"},{"key":"2258_CR17","doi-asserted-by":"crossref","unstructured":"Bano I, Horky P, Abbas SQ et al (2022) Ferroptosis: a new road towards cancer management. Molecules 27:2129","DOI":"10.3390\/molecules27072129"},{"key":"2258_CR18","doi-asserted-by":"crossref","unstructured":"Gan B (2021) Mitochondrial regulation of ferroptosis. J Cell Biol 220:e202105043","DOI":"10.1083\/jcb.202105043"},{"key":"2258_CR19","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41392-020-00216-5","volume":"5","author":"D Li","year":"2020","unstructured":"Li D, Li Y (2020) The interaction between ferroptosis and lipid metabolism in cancer. Signal Transduct Target Ther 5:108","journal-title":"Signal Transduct Target Ther"},{"key":"2258_CR20","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.molcel.2022.03.022","volume":"82","author":"D Liang","year":"2022","unstructured":"Liang D, Minikes AM, Jiang X (2022) Ferroptosis at the intersection of lipid metabolism and cellular signaling. Mol Cell 82:2215\u20132227","journal-title":"Mol Cell"},{"key":"2258_CR21","doi-asserted-by":"crossref","unstructured":"Lyamzaev KG, Panteleeva AA, Simonyan RA, Avetisyan AV, Chernyak BV (2023) Mitochondrial lipid peroxidation is responsible for ferroptosis. Cells 12:611","DOI":"10.3390\/cells12040611"},{"key":"2258_CR22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41419-023-06045-y","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Lu S, Wu LL, Yang L, Yang L, Wang J (2023) The diversified role of mitochondria in ferroptosis in cancer. Cell Death Dis 14:519","journal-title":"Cell Death Dis"},{"key":"2258_CR23","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.immuni.2024.03.019","volume":"57","author":"HN Bell","year":"2024","unstructured":"Bell HN, Stockwell BR, Zou W (2024) Ironing out the role of ferroptosis in immunity. Immunity 57:941\u2013956","journal-title":"Immunity"},{"key":"2258_CR24","doi-asserted-by":"publisher","first-page":"1329147","DOI":"10.3389\/fcell.2023.1329147","volume":"11","author":"Y Kong","year":"2023","unstructured":"Kong Y, Li J, Lin R et al (2023) Understanding the unique mechanism of ferroptosis: a promising therapeutic target. Front Cell Dev Biol 11:1329147","journal-title":"Front Cell Dev Biol"},{"key":"2258_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s43556-023-00142-2","volume":"4","author":"S Feng","year":"2023","unstructured":"Feng S, Tang D, Wang Y et al (2023) The mechanism of ferroptosis and its related diseases. Mol Biomed 4:33","journal-title":"Mol Biomed"},{"key":"2258_CR26","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s12276-023-01077-y","volume":"55","author":"JW Kim","year":"2023","unstructured":"Kim JW, Lee JY, Oh M, Lee EW (2023) An integrated view of lipid metabolism in ferroptosis revisited via lipidomic analysis. Exp Mol Med 55:1620\u20131631","journal-title":"Exp Mol Med"},{"key":"2258_CR27","doi-asserted-by":"publisher","first-page":"1269451","DOI":"10.3389\/fimmu.2023.1269451","volume":"14","author":"XD Zhang","year":"2023","unstructured":"Zhang XD, Liu ZY, Wang MS et al (2023) Mechanisms and regulations of ferroptosis. Front Immunol 14:1269451","journal-title":"Front Immunol"},{"key":"2258_CR28","doi-asserted-by":"publisher","first-page":"e995047","DOI":"10.4161\/23723556.2014.995047","volume":"2","author":"M Conrad","year":"2015","unstructured":"Conrad M, Friedmann Angeli JP (2015) Glutathione peroxidase 4 (Gpx4) and ferroptosis: What\u2019s so special about it? Mol Cell Oncol 2:e995047","journal-title":"Mol Cell Oncol"},{"key":"2258_CR29","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-021-03539-7","volume":"593","author":"C Mao","year":"2021","unstructured":"Mao C, Liu X, Zhang Y et al (2021) DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature 593:586\u2013590","journal-title":"Nature"},{"key":"2258_CR30","doi-asserted-by":"crossref","unstructured":"Mortensen MS, Ruiz J, Watts JL (2023) Polyunsaturated fatty acids drive lipid peroxidation during ferroptosis. Cells 12:804","DOI":"10.3390\/cells12050804"},{"key":"2258_CR31","doi-asserted-by":"publisher","first-page":"910292","DOI":"10.3389\/fphar.2022.910292","volume":"13","author":"FJ Li","year":"2022","unstructured":"Li FJ, Long HZ, Zhou ZW, Luo HY, Xu SG, Gao LC (2022) System X(c) (-)\/GSH\/GPX4 axis: an important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy. Front Pharmacol 13:910292","journal-title":"Front Pharmacol"},{"key":"2258_CR32","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M (2021) Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol 22:266\u2013282","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2258_CR33","doi-asserted-by":"crossref","unstructured":"Rochette L, Dogon G, Rigal E, Zeller M, Cottin Y, Vergely C (2022) Lipid peroxidation and iron metabolism: two corner stones in the homeostasis control of ferroptosis. Int J Mol Sci 24:449","DOI":"10.3390\/ijms24010449"},{"key":"2258_CR34","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME et al (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156:317\u2013331","journal-title":"Cell"},{"key":"2258_CR35","doi-asserted-by":"publisher","first-page":"100710","DOI":"10.1016\/j.crmeth.2024.100710","volume":"4","author":"T Nakamura","year":"2024","unstructured":"Nakamura T, Ito J, Mourao ASD et al (2024) A tangible method to assess native ferroptosis suppressor activity. Cell Rep Methods 4:100710","journal-title":"Cell Rep Methods"},{"key":"2258_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang L, Kon N, Li T et al (2015) Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520:57\u201362","journal-title":"Nature"},{"key":"2258_CR37","doi-asserted-by":"crossref","unstructured":"Yan R, Lin B, Jin W, Tang L, Hu S, Cai R (2023) NRF2, a superstar of ferroptosis. Antioxidants (Basel) 12:1739","DOI":"10.3390\/antiox12091739"},{"key":"2258_CR38","doi-asserted-by":"crossref","unstructured":"Zhu J, Xiong Y, Zhang Y et al (2020) The molecular mechanisms of regulating oxidative stress-induced ferroptosis and therapeutic strategy in tumors. Oxid Med Cell Longev 2020:8810785","DOI":"10.1155\/2020\/8810785"},{"key":"2258_CR39","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1021\/acscentsci.0c01592","volume":"7","author":"Y Fang","year":"2021","unstructured":"Fang Y, Chen X, Tan Q, Zhou H, Xu J, Gu Q (2021) Inhibiting ferroptosis through disrupting the NCOA4\u2013FTH1 interaction: a new mechanism of action. ACS Cent Sci 7:980\u2013989","journal-title":"ACS Cent Sci"},{"key":"2258_CR40","doi-asserted-by":"publisher","first-page":"e36830","DOI":"10.1097\/MD.0000000000036830","volume":"102","author":"J Huang","year":"2023","unstructured":"Huang J, Xu Z, Chen D, Zhou C, Shen Y (2023) Pancancer analysis reveals the role of disulfidptosis in predicting prognosis, immune infiltration and immunotherapy response in tumors. Medicine (Baltimore) 102:e36830","journal-title":"Medicine (Baltimore)"},{"key":"2258_CR41","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40364-020-00230-3","volume":"8","author":"Z Li","year":"2020","unstructured":"Li Z, Chen L, Chen C et al (2020) Targeting ferroptosis in breast cancer. Biomark Res 8:58","journal-title":"Biomark Res"},{"key":"2258_CR42","doi-asserted-by":"publisher","first-page":"1243286","DOI":"10.3389\/fphar.2023.1243286","volume":"14","author":"C Xu","year":"2023","unstructured":"Xu C, Chen Y, Yu Q, Song J, Jin Y, Gao X (2023) Compounds targeting ferroptosis in breast cancer: progress and their therapeutic potential. Front Pharmacol 14:1243286","journal-title":"Front Pharmacol"},{"key":"2258_CR43","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1158\/0008-5472.CAN-23-4042","volume":"84","author":"G Lei","year":"2024","unstructured":"Lei G, Gan B (2024) Exploring Ferroptosis-inducing therapies for cancer treatment: challenges and opportunities. Cancer Res 84:961\u2013964","journal-title":"Cancer Res"},{"key":"2258_CR44","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41392-023-01606-1","volume":"8","author":"S Sun","year":"2023","unstructured":"Sun S, Shen J, Jiang J, Wang F, Min J (2023) Targeting ferroptosis opens new avenues for the development of novel therapeutics. Signal Transduct Target Ther 8:372","journal-title":"Signal Transduct Target Ther"},{"key":"2258_CR45","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41419-023-06106-2","volume":"14","author":"S Chipurupalli","year":"2023","unstructured":"Chipurupalli S, Jiang P, Liu X, Santos JL, Marcato P, Rosen KV (2023) Three-dimensional growth sensitizes breast cancer cells to treatment with ferroptosis-promoting drugs. Cell Death Dis 14:580","journal-title":"Cell Death Dis"},{"key":"2258_CR46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cmet.2022.09.021","volume":"35","author":"F Yang","year":"2023","unstructured":"Yang F, Xiao Y, Ding JH et al (2023) Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab 35:84\u2013100e108","journal-title":"Cell Metab"},{"key":"2258_CR47","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13046-021-02012-7","volume":"40","author":"J Yang","year":"2021","unstructured":"Yang J, Zhou Y, Xie S et al (2021) Metformin induces ferroptosis by inhibiting ufmylation of SLC7A11 in breast cancer. J Exp Clin Cancer Res 40:206","journal-title":"J Exp Clin Cancer Res"},{"key":"2258_CR48","doi-asserted-by":"publisher","first-page":"174970","DOI":"10.1016\/j.ejphar.2022.174970","volume":"924","author":"Y Wei","year":"2022","unstructured":"Wei Y, Zhu Z, Hu H, Guan J, Yang B, Zhao H (2022) Eupaformosanin induces apoptosis and ferroptosis through ubiquitination of mutant p53 in triple-negative breast cancer. Eur J Pharmacol 924:174970","journal-title":"Eur J Pharmacol"},{"key":"2258_CR49","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s43018-024-00725-0","volume":"5","author":"YZ Jiang","year":"2024","unstructured":"Jiang YZ, Ma D, Jin X et al (2024) Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities. Nat Cancer 5:673\u2013690","journal-title":"Nat Cancer"},{"key":"2258_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41419-025-07354-0","volume":"16","author":"J Cao","year":"2025","unstructured":"Cao J, Zhou T, Wu T et al (2025) Targeting estrogen-regulated system x(c)(-) promotes ferroptosis and endocrine sensitivity of ER+\u2009breast cancer. Cell Death Dis 16:30","journal-title":"Cell Death Dis"},{"key":"2258_CR51","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41523-024-00685-9","volume":"10","author":"K Hu","year":"2024","unstructured":"Hu K, Qiu J, Hu Y, Wang Y, Yu C, Wu Y (2024) Efficacy of ferscore in predicting sensitivity to ferroptosis inducers in breast cancer. NPJ Breast Cancer 10:74","journal-title":"NPJ Breast Cancer"},{"key":"2258_CR52","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/cac2.12646","volume":"45","author":"C Pottier","year":"2025","unstructured":"Pottier C, Montero-Ruiz L, Jehay R et al (2025) Targeting ferroptosis resistance resensitizes metastatic HR(+)HER2(-) breast cancer cells to palbociclib-hormone therapy. Cancer Commun (Lond) 45:460\u2013464","journal-title":"Cancer Commun (Lond)"},{"key":"2258_CR53","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41419-022-04579-1","volume":"13","author":"C Chen","year":"2022","unstructured":"Chen C, Xie B, Li Z et al (2022) Fascin enhances the vulnerability of breast cancer to erastin-induced ferroptosis. Cell Death Dis 13:150","journal-title":"Cell Death Dis"},{"key":"2258_CR54","doi-asserted-by":"publisher","first-page":"102952","DOI":"10.1016\/j.redox.2023.102952","volume":"68","author":"Z Xu","year":"2023","unstructured":"Xu Z, Wang X, Sun W et al (2023) RelB-activated GPX4 inhibits ferroptosis and confers Tamoxifen resistance in breast cancer. Redox Biol 68:102952","journal-title":"Redox Biol"},{"key":"2258_CR55","doi-asserted-by":"publisher","first-page":"100974","DOI":"10.1016\/j.drup.2023.100974","volume":"69","author":"Z Zhu","year":"2023","unstructured":"Zhu Z, Shen H, Xu J et al (2023) GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells. Drug Resist Updat 69:100974","journal-title":"Drug Resist Updat"},{"key":"2258_CR56","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41467-022-30217-7","volume":"13","author":"Y Zou","year":"2022","unstructured":"Zou Y, Zheng S, Xie X et al (2022) N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun 13:2672","journal-title":"Nat Commun"},{"key":"2258_CR57","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41419-022-05242-5","volume":"13","author":"P Li","year":"2022","unstructured":"Li P, Lin Q, Sun S et al (2022) Inhibition of cannabinoid receptor type 1 sensitizes triple-negative breast cancer cells to ferroptosis via regulating fatty acid metabolism. Cell Death Dis 13:808","journal-title":"Cell Death Dis"},{"key":"2258_CR58","doi-asserted-by":"publisher","first-page":"122395","DOI":"10.1016\/j.biomaterials.2023.122395","volume":"303","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zhou K, Lin J et al (2023) Ferroptosis-enhanced chemotherapy for triple-negative breast cancer with magnetic composite nanoparticles. Biomaterials 303:122395","journal-title":"Biomaterials"},{"key":"2258_CR59","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1042\/BST20230550","volume":"52","author":"M Walravens","year":"2024","unstructured":"Walravens M, Koeken I, Vanden Berghe T (2024) Therapeutic exploitation of ferroptosis. Biochem Soc Trans 52:693\u2013706","journal-title":"Biochem Soc Trans"},{"key":"2258_CR60","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41419-022-04927-1","volume":"13","author":"D Wang","year":"2022","unstructured":"Wang D, Tang L, Zhang Y et al (2022) Regulatory pathways and drugs associated with ferroptosis in tumors. Cell Death Dis 13:544","journal-title":"Cell Death Dis"},{"key":"2258_CR61","doi-asserted-by":"crossref","unstructured":"Pearson AN, Carmicheal J, Jiang L, Lei YL, Green MD (2021) Contribution of lipid oxidation and ferroptosis to radiotherapy efficacy. Int J Mol Sci 22:12603","DOI":"10.3390\/ijms222212603"},{"key":"2258_CR62","doi-asserted-by":"publisher","first-page":"951116","DOI":"10.3389\/fcell.2022.951116","volume":"10","author":"J Su","year":"2022","unstructured":"Su J, Bian C, Zheng Z et al (2022) Cooperation effects of radiation and ferroptosis on tumor suppression and radiation injury. Front Cell Dev Biol 10:951116","journal-title":"Front Cell Dev Biol"},{"key":"2258_CR63","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.trecan.2024.01.002","volume":"10","author":"J Liu","year":"2024","unstructured":"Liu J, Kang R, Tang D (2024) Adverse effects of ferroptotic therapy: mechanisms and management. Trends Cancer 10:417\u2013429","journal-title":"Trends Cancer"},{"key":"2258_CR64","first-page":"613","volume":"17","author":"C Qiao","year":"2022","unstructured":"Qiao C, Wang H, Guan Q, Wei M, Li Z (2022) Ferroptosis-based nano delivery systems targeted therapy for colorectal cancer: insights and future perspectives. Asian J Pharm Sci 17:613\u2013629","journal-title":"Asian J Pharm Sci"},{"key":"2258_CR65","doi-asserted-by":"publisher","first-page":"13195","DOI":"10.1021\/acsnano.3c00048","volume":"17","author":"L Zeng","year":"2023","unstructured":"Zeng L, Ding S, Cao Y et al (2023) A MOF-Based potent ferroptosis inducer for enhanced radiotherapy of triple negative breast cancer. ACS Nano 17:13195\u201313210","journal-title":"ACS Nano"},{"key":"2258_CR66","doi-asserted-by":"publisher","first-page":"122447","DOI":"10.1016\/j.biomaterials.2023.122447","volume":"305","author":"TJ Zhou","year":"2024","unstructured":"Zhou TJ, Zhang MM, Liu DM et al (2024) Glutathione depletion and dihydroorotate dehydrogenase Inhibition actuated ferroptosis-augment to surmount triple-negative breast cancer. Biomaterials 305:122447","journal-title":"Biomaterials"},{"key":"2258_CR67","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41419-022-05384-6","volume":"13","author":"Q Dang","year":"2022","unstructured":"Dang Q, Sun Z, Wang Y, Wang L, Liu Z, Han X (2022) Ferroptosis: a double-edged sword mediating immune tolerance of cancer. Cell Death Dis 13:925","journal-title":"Cell Death Dis"},{"key":"2258_CR68","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/imr.13235","volume":"321","author":"D Tang","year":"2024","unstructured":"Tang D, Kroemer G, Kang R (2024) Ferroptosis in immunostimulation and immunosuppression. Immunol Rev 321:199\u2013210","journal-title":"Immunol Rev"},{"key":"2258_CR69","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.tips.2023.06.005","volume":"44","author":"R Kim","year":"2023","unstructured":"Kim R, Taylor D, Vonderheide RH, Gabrilovich DI (2023) Ferroptosis of immune cells in the tumor microenvironment. Trends Pharmacol Sci 44:542\u2013552","journal-title":"Trends Pharmacol Sci"},{"key":"2258_CR70","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.actbio.2024.03.030","volume":"180","author":"X Zhu","year":"2024","unstructured":"Zhu X, Xie L, Tian J, Jiang Y, Song E, Song Y (2024) A multi-mode Rhein-based nano-platform synergizing ferrotherapy\/chemotherapy-induced immunotherapy for enhanced tumor therapy. Acta Biomater 180:383\u2013393","journal-title":"Acta Biomater"},{"key":"2258_CR71","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.bbrc.2019.01.090","volume":"510","author":"Q Wen","year":"2019","unstructured":"Wen Q, Liu J, Kang R, Zhou B, Tang D (2019) The release and activity of HMGB1 in ferroptosis. Biochem Biophys Res Commun 510:278\u2013283","journal-title":"Biochem Biophys Res Commun"},{"key":"2258_CR72","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","volume":"31","author":"D Tang","year":"2021","unstructured":"Tang D, Chen X, Kang R, Kroemer G (2021) Ferroptosis: molecular mechanisms and health implications. Cell Res 31:107\u2013125","journal-title":"Cell Res"},{"key":"2258_CR73","doi-asserted-by":"crossref","unstructured":"Desterke C, Xiang Y, Elhage R, Duruel C, Chang Y, Hamai A (2023) Ferroptosis inducers upregulate PD-L1 in recurrent Triple-Negative breast cancer. Cancers (Basel) 16:155","DOI":"10.3390\/cancers16010155"},{"key":"2258_CR74","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00018-023-04907-4","volume":"80","author":"Y Ren","year":"2023","unstructured":"Ren Y, Mao X, Xu H et al (2023) Ferroptosis and EMT: key targets for combating cancer progression and therapy resistance. Cell Mol Life Sci 80:263","journal-title":"Cell Mol Life Sci"},{"key":"2258_CR75","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41419-023-05972-0","volume":"14","author":"Y Liang","year":"2023","unstructured":"Liang Y, Wang Y, Zhang Y et al (2023) HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF-kappaB signaling pathway in breast cancer. Cell Death Dis 14:434","journal-title":"Cell Death Dis"},{"key":"2258_CR76","doi-asserted-by":"publisher","first-page":"1026954","DOI":"10.3389\/fimmu.2022.1026954","volume":"13","author":"C Kerneur","year":"2022","unstructured":"Kerneur C, Cano CE, Olive D (2022) Major pathways involved in macrophage polarization in cancer. Front Immunol 13:1026954","journal-title":"Front Immunol"},{"key":"2258_CR77","doi-asserted-by":"publisher","first-page":"888713","DOI":"10.3389\/fimmu.2022.888713","volume":"13","author":"J Gao","year":"2022","unstructured":"Gao J, Liang Y, Wang L (2022) Shaping polarization of tumor-associated macrophages in cancer immunotherapy. Front Immunol 13:888713","journal-title":"Front Immunol"},{"key":"2258_CR78","doi-asserted-by":"crossref","unstructured":"Mao Z, Hu Y, Zhao Y et al (2024) The mutual regulatory role of ferroptosis and immunotherapy in anti-tumor therapy. Apoptosis 29:1291\u20131308","DOI":"10.1007\/s10495-024-01988-9"},{"key":"2258_CR79","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1111\/jcmm.17529","volume":"26","author":"C Gong","year":"2022","unstructured":"Gong C, Ji Q, Wu M et al (2022) Ferroptosis in tumor immunity and therapy. J Cell Mol Med 26:5565\u20135579","journal-title":"J Cell Mol Med"},{"key":"2258_CR80","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bbcan.2017.10.007","volume":"1869","author":"M Santoni","year":"2018","unstructured":"Santoni M, Romagnoli E, Saladino T et al (2018) Triple negative breast cancer: key role of Tumor-Associated macrophages in regulating the activity of anti-PD-1\/PD-L1 agents. Biochim Biophys Acta Rev Cancer 1869:78\u201384","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2258_CR81","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41419-022-04775-z","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang Y, Wang Y, Guo L, Gao W, Tang TL, Yan M (2022) Interaction between macrophages and ferroptosis. Cell Death Dis 13:355","journal-title":"Cell Death Dis"},{"key":"2258_CR82","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-021-01223-x","volume":"15","author":"H Li","year":"2022","unstructured":"Li H, Yang P, Wang J et al (2022) HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk. J Hematol Oncol 15:2","journal-title":"J Hematol Oncol"},{"key":"2258_CR83","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1038\/s41467-022-31218-2","volume":"13","author":"B Wiernicki","year":"2022","unstructured":"Wiernicki B, Maschalidi S, Pinney J et al (2022) Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity. Nat Commun 13:3676","journal-title":"Nat Commun"},{"key":"2258_CR84","doi-asserted-by":"crossref","unstructured":"Desterke C, Cosialls E, Xiang Y et al (2023) Adverse crosstalk between extracellular matrix remodeling and ferroptosis in basal breast cancer. Cells 12:2176","DOI":"10.3390\/cells12172176"},{"key":"2258_CR85","doi-asserted-by":"publisher","first-page":"1084887","DOI":"10.3389\/fimmu.2023.1084887","volume":"14","author":"A Tiwari","year":"2023","unstructured":"Tiwari A, Oravecz T, Dillon LA et al (2023) Towards a consensus definition of immune exclusion in cancer. Front Immunol 14:1084887","journal-title":"Front Immunol"},{"key":"2258_CR86","doi-asserted-by":"crossref","unstructured":"Clifton GT, Rothenberg M, Ascierto PA et al (2023) Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop. J Immunother Cancer 11:e006773","DOI":"10.1136\/jitc-2023-006773"},{"key":"2258_CR87","doi-asserted-by":"publisher","first-page":"818453","DOI":"10.3389\/fcell.2022.818453","volume":"10","author":"J Deng","year":"2022","unstructured":"Deng J, Zhou M, Liao T et al (2022) Targeting cancer cell ferroptosis to reverse immune checkpoint inhibitor therapy resistance. Front Cell Dev Biol 10:818453","journal-title":"Front Cell Dev Biol"},{"key":"2258_CR88","doi-asserted-by":"publisher","first-page":"109235","DOI":"10.1016\/j.celrep.2021.109235","volume":"35","author":"C Xu","year":"2021","unstructured":"Xu C, Sun S, Johnson T et al (2021) The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. Cell Rep 35:109235","journal-title":"Cell Rep"},{"key":"2258_CR89","doi-asserted-by":"crossref","unstructured":"Lee J, Roh JL (2022) SLC7A11 as a gateway of metabolic perturbation and ferroptosis vulnerability in cancer. Antioxidants (Basel) 11:2444","DOI":"10.3390\/antiox11122444"},{"key":"2258_CR90","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang W, Green M, Choi JE et al (2019) CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569:270\u2013274","journal-title":"Nature"},{"key":"2258_CR91","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13046-023-02925-5","volume":"43","author":"Y Hua","year":"2024","unstructured":"Hua Y, Yang S, Zhang Y et al (2024) Modulating ferroptosis sensitivity: environmental and cellular targets within the tumor microenvironment. J Exp Clin Cancer Res 43:19","journal-title":"J Exp Clin Cancer Res"},{"key":"2258_CR92","doi-asserted-by":"publisher","first-page":"1255443","DOI":"10.3389\/fimmu.2023.1255443","volume":"14","author":"Z Lin","year":"2023","unstructured":"Lin Z, Zou S, Wen K (2023) The crosstalk of CD8+\u2009T cells and ferroptosis in cancer. Front Immunol 14:1255443","journal-title":"Front Immunol"},{"key":"2258_CR93","doi-asserted-by":"crossref","unstructured":"Jiang Z, Lim SO, Yan M et al (2021) TYRO3 induces anti-PD-1\/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J Clin Invest 131","DOI":"10.1172\/JCI139434"},{"key":"2258_CR94","doi-asserted-by":"publisher","first-page":"e2307","DOI":"10.1038\/cddis.2016.208","volume":"7","author":"S Ma","year":"2016","unstructured":"Ma S, Henson ES, Chen Y, Gibson SB (2016) Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis 7:e2307","journal-title":"Cell Death Dis"},{"key":"2258_CR95","doi-asserted-by":"publisher","first-page":"32280","DOI":"10.18632\/oncotarget.25794","volume":"9","author":"L Cobler","year":"2018","unstructured":"Cobler L, Zhang H, Suri P, Park C, Timmerman LA (2018) xCT inhibition sensitizes tumors to gamma-radiation via glutathione reduction. Oncotarget 9:32280\u201332297","journal-title":"Oncotarget"},{"key":"2258_CR96","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.7150\/thno.52028","volume":"11","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Lu M, Chen C et al (2021) Holo-lactoferrin: the link between ferroptosis and radiotherapy in triple-negative breast cancer. Theranostics 11:3167\u20133182","journal-title":"Theranostics"},{"key":"2258_CR97","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12935-020-1100-y","volume":"20","author":"K Khorsandi","year":"2020","unstructured":"Khorsandi K, Kianmehr Z, Hosseinmardi Z, Hosseinzadeh R (2020) Anti-cancer effect of Gallic acid in presence of low level laser irradiation: ROS production and induction of apoptosis and ferroptosis. Cancer Cell Int 20:18","journal-title":"Cancer Cell Int"},{"key":"2258_CR98","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/path.5104","volume":"246","author":"S Tury","year":"2018","unstructured":"Tury S, Assayag F, Bonin F et al (2018) The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers. J Pathol 246:103\u2013114","journal-title":"J Pathol"},{"key":"2258_CR99","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1021\/acsnano.1c08664","volume":"16","author":"K Li","year":"2022","unstructured":"Li K, Lin C, Li M et al (2022) Multienzyme-like reactivity cooperatively impairs glutathione peroxidase 4 and ferroptosis suppressor protein 1 pathways in triple-negative breast cancer for sensitized ferroptosis therapy. ACS Nano 16:2381\u20132398","journal-title":"ACS Nano"},{"key":"2258_CR100","doi-asserted-by":"publisher","first-page":"e2102799","DOI":"10.1002\/adhm.202102799","volume":"11","author":"J Yang","year":"2022","unstructured":"Yang J, Jia Z, Zhang J et al (2022) Metabolic intervention nanoparticles for triple-negative breast cancer therapy via overcoming FSP1-mediated ferroptosis resistance. Adv Healthc Mater 11:e2102799","journal-title":"Adv Healthc Mater"},{"key":"2258_CR101","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41419-023-06042-1","volume":"14","author":"SY Park","year":"2023","unstructured":"Park SY, Jeong KJ, Poire A et al (2023) Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer. Cell Death Dis 14:532","journal-title":"Cell Death Dis"},{"key":"2258_CR102","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13058-019-1177-1","volume":"21","author":"A Nagpal","year":"2019","unstructured":"Nagpal A, Redvers RP, Ling X et al (2019) Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2(+ve) breast cancer metastasis. Breast Cancer Res 21:94","journal-title":"Breast Cancer Res"},{"key":"2258_CR103","doi-asserted-by":"publisher","first-page":"121222","DOI":"10.1016\/j.lfs.2022.121222","volume":"312","author":"E Ozkan","year":"2023","unstructured":"Ozkan E, Bakar-Ates F (2023) Etoposide in combination with Erastin synergistically altered iron homeostasis and induced ferroptotic cell death through regulating IREB2\/FPN1 expression in Estrogen receptor positive-breast cancer cells. Life Sci 312:121222","journal-title":"Life Sci"},{"key":"2258_CR104","first-page":"826","volume":"42","author":"H Yu","year":"2019","unstructured":"Yu H, Yang C, Jian L et al (2019) Sulfasalazine-induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of Estrogen receptor on the transferrin receptor. Oncol Rep 42:826\u2013838","journal-title":"Oncol Rep"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02258-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02258-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02258-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T08:01:54Z","timestamp":1774080114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02258-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":104,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2258"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02258-6","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"49"}}